文献速递胸部肿瘤放疗放疗物理与技术

中央及超中央型肺肿瘤SBRT后放射性心脏毒性:多中心回顾性队列研究

Radiation-induced cardiac toxicity after SBRT for central and ultracentral lung tumors: A multicenter retrospective cohort study.
PubMed 文献 · Radiother Oncol · 2026-07-11

该多中心回顾性队列纳入2016—2023年法国3家癌症中心接受SBRT的中央或超中央型肺肿瘤成人患者,共162例可评估心脏毒性。SBRT后≥6个月发生≥2级心脏毒性者13例(8.0%;95%CI 4.7–13.2%),中位发生时间12.6个月;探索性多变量分析中既往卒中和肺原发肿瘤与心脏毒性相关。

要点

  • 中央/超中央型肺肿瘤SBRT后症状性心脏毒性不常见但临床相关。
  • ≥2级心脏毒性发生率8.0%,中位发生时间12.6个月。
  • 既往卒中与肺原发肿瘤在探索性分析中与心脏毒性相关。

核心结论

  • 中央及超中央型肺肿瘤SBRT后症状性心脏毒性不常见但具有临床意义,支持在前瞻性队列中进一步评估风险适配的心脏监测策略。

研究设计与样本

  • 多中心回顾性队列研究,纳入2016—2023年法国3家癌症中心接受SBRT的中央或超中央型肺肿瘤成人患者,按SUNSET定义分类。
  • 随访不足6个月者被排除于主要心脏毒性分析,最终162例可评估。
  • 心脏毒性按CTCAE v5.0分级,定义为SBRT开始后≥6个月发生的≥2级心脏事件。

主要发现

  • 13例(8.0%;95%CI 4.7–13.2%)发生≥2级心脏毒性,中位发生时间为SBRT后12.6个月。
  • 探索性多变量关联分析中,既往卒中(OR 4.17;95%CI 1.09–15.98)和肺原发肿瘤(OR 4.03;95%CI 1.12–14.42)与心脏毒性相关。
  • 24个月时病灶水平局部控制率为78.3%,总生存率为83.4%(95%CI 73.8–89.7)。
  • 探索性生存分析中,头颈原发肿瘤和较低处方EQD2与总生存相关。

关键数值与推荐

  • 心脏毒性定义:CTCAE v5.0分级≥2级且发生于SBRT开始后≥6个月。
  • 单变量分析中p<0.10的变量进入Firth惩罚多变量逻辑回归。
  • 总生存采用Kaplan-Meier估计,并用Firth校正Cox模型探索。

临床怎么用

  • 对中央或超中央型肺肿瘤SBRT患者,应关注SBRT后≥6个月的心脏症状并考虑风险适配的心脏监测。
  • 既往有卒中史或肺原发肿瘤的患者在探索性分析中风险较高,可作为临床关注线索。

局限性

  • 本研究为回顾性多中心队列,心脏毒性分析排除了随访不足6个月的患者。
  • 心脏毒性与生存相关因素的分析为探索性,需前瞻性队列进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Central and ultracentral lung tumors are increasingly treated with ablative-dose stereotactic body radiation therapy (SBRT) near cardiac structures, raising concerns regarding radiation-induced heart disease. This study evaluated the prevalence, timing, and clinical factors associated with symptomatic cardiac toxicity following SBRT. METHODS: This retrospective multicenter cohort included adults treated with SBRT for central or ultracentral lung tumors at three French cancer centers between 2016 and 2023, classified according to SUNSET definitions. Patients with < 6 months of follow-up were excluded from the primary cardiac-toxicity analysis, leaving 162 evaluable patients. Cardiac toxicity was graded using CTCAE v5.0, considering grade ≥ 2 cardiac events occurring ≥ 6 months after SBRT initiation. Variables associated with toxicity at p < 0.10 in univariable analysis were entered into Firth-penalized multivariable logistic regression. Overall survival (OS) was estimated using Kaplan-Meier and explored using Firth-corrected Cox models. RESULTS: Grade ≥ 2 cardiac toxicity occurred in 13 patients (8.0%; 95% CI, 4.7-13.2%), with a median onset of 12.6 months after SBRT. In exploratory multivariable association analysis, prior stroke (OR 4.17; 95% CI, 1.09-15.98) and pulmonary primary tumors (OR 4.03; 95% CI, 1.12-14.42) were associated with cardiac toxicity. At 24 months, lesion-level local control was 78.3%, and OS was 83.4% (95% CI, 73.8-89.7). In exploratory survival analysis, head-and-neck primary tumors and lower prescription EQD2 were associated with OS. CONCLUSIONS: Symptomatic cardiac toxicity after SBRT for central and ultracentral lung tumors was uncommon but clinically relevant. These findings support further evaluation of risk-adapted cardiac monitoring strategies in prospective cohorts.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Licha A, Felici F, Bouazzi L, et al. Radiation-induced cardiac toxicity after SBRT for central and ultracentral lung tumors: A multicenter retrospective cohort study. Radiother Oncol. 2026. PMID: 42435816. doi:10.1016/j.radonc.2026.111694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。